search
Back to results

Misoprostol in the Treatment of Postpartum Hemorrhage

Primary Purpose

Postpartum Hemorrhage

Status
Completed
Phase
Not Applicable
Locations
Pakistan
Study Type
Interventional
Intervention
Misoprostol
Sponsored by
Gynuity Health Projects
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Postpartum Hemorrhage focused on measuring Postpartum Haemorrhage, Misoprostol

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria: All women delivering vaginally with clinically diagnosed PPH requiring uterotonics Exclusion Criteria: Refusal to give consent for participation or if the woman is too distressed to give consent Woman is not entitled to give informed consent (e.g. minors without a guardian) Woman who had a caesarean section Delivery is regarded as abortion (gestational age < 28 weeks)

Sites / Locations

  • Aga Khan University Hospital
  • The Aga Khan Health Services

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Misoprostol

Placebo

Arm Description

three tablets of active misoprostol (600 mcg) given sublingually

three tablets resembling misoprostol given sublingually

Outcomes

Primary Outcome Measures

Blood loss greater than or equal to 500 mls after enrolment

Secondary Outcome Measures

Average blood loss
Clinical complications (need for transfusion, hysterectomy)
Pre-delivery and post-delivery hemoglobin measures
Side effects

Full Information

First Posted
June 29, 2005
Last Updated
March 17, 2009
Sponsor
Gynuity Health Projects
Collaborators
Aga Khan University, Aga Khan Health Services, The Aga Khan Foundation, Family Care International
search

1. Study Identification

Unique Protocol Identification Number
NCT00116480
Brief Title
Misoprostol in the Treatment of Postpartum Hemorrhage
Official Title
Misoprostol in the Treatment of Post Partum Hemorrhage: A Placebo Randomised Controlled Trial in 4 Karachi Hospitals
Study Type
Interventional

2. Study Status

Record Verification Date
March 2009
Overall Recruitment Status
Completed
Study Start Date
December 2005 (undefined)
Primary Completion Date
April 2007 (Actual)
Study Completion Date
April 2007 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Gynuity Health Projects
Collaborators
Aga Khan University, Aga Khan Health Services, The Aga Khan Foundation, Family Care International

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Postpartum haemorrhage (PPH) remains a leading cause of maternal mortality, despite treatment with conventional methods. Uncontrolled reports and three small randomised controlled trials have suggested that misoprostol may have an additive effect to routine treatment, and there is a serious danger that this method will be used widely without research to document the effectiveness or risks of this method. In this randomised controlled trial (RCT), we propose to test whether 600 μg of sublingually administered misoprostol in women requiring additional uterotonics after delivery, and after routine syntocinon to all women during or after delivery, has additional effects above the additional conventional uterotonics in reducing PPH. Women with measured blood loss greater than or equal to 500 mls in 4 Karachi hospitals who give consent will be given locally routine treatment for PPH. In addition, they will be enrolled by drawing the next of a series of randomised treatment packs containing misoprostol or placebo. The primary outcome measure will be blood loss greater than or equal to 500 mls after enrolment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Postpartum Hemorrhage
Keywords
Postpartum Haemorrhage, Misoprostol

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
61 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Misoprostol
Arm Type
Experimental
Arm Description
three tablets of active misoprostol (600 mcg) given sublingually
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
three tablets resembling misoprostol given sublingually
Intervention Type
Drug
Intervention Name(s)
Misoprostol
Intervention Description
600 mcg of sublingual misoprostol
Primary Outcome Measure Information:
Title
Blood loss greater than or equal to 500 mls after enrolment
Time Frame
Blood loss measured for minimum of 1 hour or until active bleeding ceased
Secondary Outcome Measure Information:
Title
Average blood loss
Time Frame
Blood loss measured for minimum of one hour or until active bleeding ceased
Title
Clinical complications (need for transfusion, hysterectomy)
Time Frame
After delivery and prior to hospital discharge
Title
Pre-delivery and post-delivery hemoglobin measures
Time Frame
Pre-delivery hemoglobin measured upon admission to hospital (during labor) and measured postpartum 12-24 hours after delivery
Title
Side effects
Time Frame
observed or reported following study treatment and prior to discharge

10. Eligibility

Sex
Female
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: All women delivering vaginally with clinically diagnosed PPH requiring uterotonics Exclusion Criteria: Refusal to give consent for participation or if the woman is too distressed to give consent Woman is not entitled to give informed consent (e.g. minors without a guardian) Woman who had a caesarean section Delivery is regarded as abortion (gestational age < 28 weeks)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nadeem F Zuberi, MD
Organizational Affiliation
Aga Khan University Hospital, Karachi
Official's Role
Principal Investigator
Facility Information:
Facility Name
Aga Khan University Hospital
City
Karachi
Country
Pakistan
Facility Name
The Aga Khan Health Services
City
Karachi
Country
Pakistan

12. IPD Sharing Statement

Citations:
PubMed Identifier
33232518
Citation
Parry Smith WR, Papadopoulou A, Thomas E, Tobias A, Price MJ, Meher S, Alfirevic Z, Weeks AD, Hofmeyr GJ, Gulmezoglu AM, Widmer M, Oladapo OT, Vogel JP, Althabe F, Coomarasamy A, Gallos ID. Uterotonic agents for first-line treatment of postpartum haemorrhage: a network meta-analysis. Cochrane Database Syst Rev. 2020 Nov 24;11(11):CD012754. doi: 10.1002/14651858.CD012754.pub2.
Results Reference
derived
PubMed Identifier
18718007
Citation
Zuberi NF, Durocher J, Sikander R, Baber N, Blum J, Walraven G. Misoprostol in addition to routine treatment of postpartum hemorrhage: a hospital-based randomized-controlled trial in Karachi, Pakistan. BMC Pregnancy Childbirth. 2008 Aug 21;8:40. doi: 10.1186/1471-2393-8-40.
Results Reference
derived
Links:
URL
http://www.gynuity.org
Description
Related Info

Learn more about this trial

Misoprostol in the Treatment of Postpartum Hemorrhage

We'll reach out to this number within 24 hrs